This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sommer, B. R. Articles by Dorsey, F. Search for Related Content PubMed Articles by Sommer, B. R. Articles by Dorsey, F. Social Bookmarking                         What's this?

Changes in Tardive Dyskinesia Symptoms in Elderly Patients Treated with Ganglioside GM1 or Placebo

Department of Psychiatry (Dr. Sommer), Mount Sinai School of Medicine, New York, New York; from the Department of Psychiatry, SUNY at Stony Brook, Stony Brook, New York; from the Mailman Research Center and McLean Hospital, (Drs. Cohen, Satlin, and Cole), Harvard Medical School, Belmont, Massachusetts; and from the FIDIA Pharmaceutical Corporation, (Dr. Dorsey) Washington, District of Columbia.

Bruce M. Cohen, MD, PhD

Department of Psychiatry (Dr. Sommer), Mount Sinai School of Medicine, New York, New York; from the Department of Psychiatry, SUNY at Stony Brook, Stony Brook, New York; from the Mailman Research Center and McLean Hospital, (Drs. Cohen, Satlin, and Cole), Harvard Medical School, Belmont, Massachusetts; and from the FIDIA Pharmaceutical Corporation, (Dr. Dorsey) Washington, District of Columbia.

Andrew Satlin, MD

Department of Psychiatry (Dr. Sommer), Mount Sinai School of Medicine, New York, New York; from the Department of Psychiatry, SUNY at Stony Brook, Stony Brook, New York; from the Mailman Research Center and McLean Hospital, (Drs. Cohen, Satlin, and Cole), Harvard Medical School, Belmont, Massachusetts; and from the FIDIA Pharmaceutical Corporation, (Dr. Dorsey) Washington, District of Columbia.

Jonathan O. Cole, MD

Department of Psychiatry (Dr. Sommer), Mount Sinai School of Medicine, New York, New York; from the Department of Psychiatry, SUNY at Stony Brook, Stony Brook, New York; from the Mailman Research Center and McLean Hospital, (Drs. Cohen, Satlin, and Cole), Harvard Medical School, Belmont, Massachusetts; and from the FIDIA Pharmaceutical Corporation, (Dr. Dorsey) Washington, District of Columbia.

Lina Jandorf, MA

Department of Psychiatry (Dr. Sommer), Mount Sinai School of Medicine, New York, New York; from the Department of Psychiatry, SUNY at Stony Brook, Stony Brook, New York; from the Mailman Research Center and McLean Hospital, (Drs. Cohen, Satlin, and Cole), Harvard Medical School, Belmont, Massachusetts; and from the FIDIA Pharmaceutical Corporation, (Dr. Dorsey) Washington, District of Columbia.

Frank Dorsey, PhD

Department of Psychiatry (Dr. Sommer), Mount Sinai School of Medicine, New York, New York; from the Department of Psychiatry, SUNY at Stony Brook, Stony Brook, New York; from the Mailman Research Center and McLean Hospital, (Drs. Cohen, Satlin, and Cole), Harvard Medical School, Belmont, Massachusetts; and from the FIDIA Pharmaceutical Corporation, (Dr. Dorsey) Washington, District of Columbia.

The unique role of ganglioside GM1 in neuronal plasticity led two centers, New York University and McLean Hospital, to study the effect of GM1 or placebo in patients with tardive dyskinesia. Results from the NYU cohort have already been published. We now present data from the entire cohort, allowing us to evaluate the effects of GM1 in the elderly compared to young adults. Subjects with tardive dyskinesia were randomly assigned to single-blind placebo injections for 1 week, followed by 1 month of double-blind intramuscular placebo or GM1100 mg. The final sample included 29 patients: 12 younger than 55 years of age and 17 older. There was no GM1-versus-placebo difference observed in either-age group, or in the total group. However, whether on placebo or GM1, repeated measures analysis of variance (RANOVA) found a significant difference in response between Abnormal Involuntary Movement Scale scores, taken baseline and week 4, in the elderly compared to young adults. Scores for the young adults show initial improvement then deterioration back to baseline, and those for the elderly show continuing improvement during the 4-week trial. The importance of the placebo effect in the elderly and its meaning for studies of GM1 in tardive dyskinesia are discussed.

Journal of Geriatric Psychiatry and Neurology, Vol. 7, No. 4, 234-237 (1994)
DOI: 10.1177/089198879400700408


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?